Padagis Us Patent-Cliff Exposure & CMS Drug Spending Portfolio

Padagis Us (US): 3 reconciled FDA prescription therapies (6.4% 2025 to 2030 cliff risk), $15.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure6.4%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$15.0M
2024 Medicare Part D Spend$10.2M
2024 Medicaid Spend$4.8M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel